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REVIEWS AND COMMENTARY • REVIEW
Laboratory assessments of myeloma disease activity di-rect treatment decisions in multiple myeloma (1) and 
contribute to clinical risk stratification systems such as the 
Revised International Staging System for Multiple My-
eloma and gene expression profiling classifiers (2,3). 
Conversely, skeletal survey, which has been in widespread 
use for decades, only offers a crude assessment of bone 
involvement as a myeloma-defining event. More recently, 
some centers have escalated imaging by replacing skeletal 
survey with low-dose whole-body CT, which has greater 
sensitivity (4). However, because skeletal survey and CT 
predominantly help to detect the destructive effects of 
myeloma disease on trabecular and cortical bone rather 
than disease within the bone marrow space, sensitiv-
ity and capability as a restaging tool are inherently lim-
ited (5,6) (although imaging of bone destruction may be 
helpful for surgical planning). Myeloma infiltrates within 
bone marrow can be depicted with CT if they lie within 
the marrow spaces of long bones where they stand out 
against fatty bone marrow (7). However, in trabecular 
bone such as in the vertebral bodies, myeloma infiltrates 
are difficult to assess due to the trabeculae themselves and 
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Whole-body MRI as currently used includes DW MRI se-
quences that are sensitive to cellular density and viability and 
are important for disease detection, monitoring, and therapy 
response assessments. Inclusion of DW MRI allows highly sensi-
tive and quantitative evaluation of soft tissue and bone marrow, 
which is widely available and quick to perform and interpret. 
The relationship of apparent diffusion coefficient (ADC) (in 
square micrometers per second) values with cell density permits 
response assessments ahead of changes in lesion size, in addition 
to assessments of response heterogeneity (8,30–32).
Whole-body MRI including DW MRI has become estab-
lished as the most sensitive technique for bone marrow imaging 
(23–25) with additional benefits of speed, coverage, and quanti-
fication in comparison with traditional MRI, obviating intrave-
nous injections and radiation exposure. Wide anatomic coverage 
is essential because 50% of lesions would be missed by imaging 
the spine alone (33). Avoidance of ionizing radiation is likely to 
become increasingly relevant as surveillance imaging of high-risk 
patients with monoclonal gammopathy of undetermined signifi-
cance and of those with smoldering disease gains momentum. 
Whole-body MRI is a generally well-tolerated technique (24) 
that offers the additional benefits of assessing skeletal complica-
tions, such as spinal canal and/or nerve root compression, and is 
the most accurate method for differentiating benign from malig-
nant vertebral compression fractures (34).
Although the International Myeloma Working Group has 
taken a pragmatic approach in recommending a range of pos-
sible imaging investigations (including low-dose CT, FDG 
PET/CT, and MRI) for patients with a new potential diag-
nosis of myeloma, the high sensitivity of whole-body MRI is 
explicitly acknowledged (6,35) and it is now recommended as 
first-line imaging for all patients with a suspected diagnosis of 
asymptomatic myeloma or solitary bone plasmacytoma. In the 
United Kingdom, whole-body MRI is recommended as first-
line imaging for all patients with a suspected new diagnosis 
of myeloma (26). Recently, the British Society for Haematol-
ogy additionally recommended the use of whole-body MRI for 
monitoring response of nonsecretory myeloma, oligosecretory 
myeloma (which can occur at relapse in patients with previ-
ous secretory disease), and for those patients with extramedul-
lary disease (36). The uses of whole-body MRI in myeloma are 
summarized in Figure 1.
Acknowledging the increasingly important role of whole-body 
MRI for directing patient care in myeloma, a multidisciplinary, 
international, and expert panel of radiologists, medical physicists, 
and hematologists with experience in whole-body MRI in my-
eloma convened to discuss the performance standards, merits, and 
limitations of currently available imaging methods. The recently 
published Metastasis Reporting and Data System for Prostate 
Cancer, or MET-RADS, guidelines on the use of whole-body 
MRI for metastasis evaluations (37) were used as a model to for-
mulate the performance standards for whole-body MRI use in the 
assessment of involvement by myeloma. The Myeloma Response 
Assessment and Diagnosis System (MY-RADS) imaging recom-
mendations are designed to promote standardization and dimin-
ish variations in the acquisition, interpretation, and reporting of 
whole-body MRI in myeloma. The system also provides a means 
Abbreviations
ADC = apparent diffusion coefficient, DW = diffusion weighted, FDG = 
fluorodeoxyglucose, MY-RADS = Myeloma Response Assessment and 
Diagnosis System
Summary
This Myeloma Response Assessment and Diagnosis System, or MY-
RADS, consensus on whole-body MRI in myeloma proposes a core 
clinical protocol for whole-body MRI and an extended protocol for 
advanced assessments.
Essentials
 n Whole-body MRI is now incorporated into international stan-
dards for imaging patients with myeloma.
 n Core clinical and comprehensive protocols for whole-body MRI 
include anatomic and functional imaging and can be completed in 
30 minutes and 50 minutes, respectively.
 n Standardized acquisition protocols and structured reporting will 
support clinical deployment, training, and research in imaging of 
myeloma.
the copresence of degenerative changes, benign lesions, and os-
teoporosis in the population at risk.
The excellent soft-tissue contrast of MRI allows direct imaging 
of the bone marrow, providing high sensitivity (8–11). Perhaps 
the clearest benefit of using MRI is the early detection of focal my-
eloma disease. It is well established that patients with unequivo-
cal focal lesions at MRI have poorer outcomes. If disease can be 
detected early, and patients are stratified and treated according to 
clinical risk, then survival advantages are conferred (12–19). Fur-
thermore, most patients with apparently solitary plasmacytoma at 
skeletal surveys are upstaged with MRI, which profoundly influ-
ences treatment strategies (11,12). The number and sizes of focal 
lesions at MRI have also been shown to predict outcome (20,21). 
Fluorodeoxyglucose (FDG) PET/CT can also be used for diag-
nosis of focal bone lesions; however, MRI is more sensitive for 
diagnosis and contemporary MRI techniques have increased the 
advantage (22–25) (sensitivity of diffusion-weighted [DW] imag-
ing has been reported as 77% compared with 47% for FDG PET/
CT) (23). Gene expression profiling has revealed lower expression 
of hexokinase 2, which is involved in the glycolysis pathway, in 
lesions that are negative at FDG PET and positive at MRI. The 
prognostic significance of lesions that are discrepant between MRI 
and FDG PET/CT is not yet known (25). However, whole-body 
MRI does result in the largest rise in quality-adjusted life years 
compared with CT or FDG PET/CT (26).
Although whole-body DW MRI has emerged as one of the 
most sensitive tools for imaging bone marrow with increased lesion 
conspicuity compared with conventional MRI sequences (27–29), 
some debate remains as to its specificity. There are few studies re-
lating to myeloma. Although Lecouvet et al (28) presented data 
to suggest high specificity for detection of metastatic bone disease 
(98%–100%), a recent meta-analysis showed a pooled specificity 
of 86.1% (29). The paucity of myeloma-specific prospective stud-
ies and marked heterogeneity in reference standards make current 
judgments on specificity challenging, and biopsy of all lesions is 
not feasible. The approach offered by the International Myeloma 
Working Group of 3–6-month follow-up of equivocal solitary 
small lesions is a pragmatic solution (6).
Messiou et al
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Figure 1: Image shows current guidelines on imaging from International Myeloma 
Working Group (IMWG), National Institute for Clinical Excellence, and British Soci-
ety of Haematology. Source.—References 6, 26, 36. FDG = fluorodeoxyglucose.
for response assessment and standardized protocols 
to facilitate data sharing for future developments.
Whole-Body MRI Data Acquisition 
and Analysis
The core clinical protocol for whole-body MRI 
when used alone is designed for myeloma detection 
in bone marrow but can also image extramedullary 
disease and should be completed within 30 minutes 
of imaging time (Table 1). More comprehensive as-
sessments can be performed within 45–50 minutes 
of imaging time (Table 1). Details of machine setup, 
sequence specification, quality assurance procedures, 
and quality control and radiographic aspects can be 
found in Table E3 (Appendix E1 [online]).
The core protocol for whole-body MRI is ad-
equate for the detection of disease at diagnosis. 
Comprehensive assessments are recommended for 
assessment of soft tissue, extramedullary disease, or 
for those patients in whom serial tumor response 
assessments (including clinical trials) are planned.
Clinical Information
The following information should ideally be 
available to radiologists at the time of reporting 
(and increasing use of electronic patient records 
increases the feasibility of this): time of initial di-
agnosis or suspected diagnosis, serum paraprotein 
levels and light chain levels and trephine status 
(if performed, including site), symptomatic sites 
including any clinical indication of cord or nerve 
root compression, first line or relapse state, cur-
rent treatment, history of autograft or allograft transplant, 
details of previous radiation therapy or surgical interventions 
including vertebroplasty, granulocyte colony–stimulating factor 
or steroid administration, and minimal residual disease status 
(if performed).
Assessing Images from Whole-Body MRI
Multisequence evaluations should be performed by using all im-
ages from DW MRI (low, intermediate [if obtained], and high 
b values and ADC maps) in conjunction with the anatomic and 
fat fraction images by using image linking and scrolling worksta-
tion facilities and coregistration tools as diagnostic aids.
Maximum intensity projections of high b-value images 
displayed by using the inverted gray scale are useful for global 
tumor volume assessments and for localizing regional tumor 
distribution. These images are able to display disease (eg, for 
referring clinicians in multidisciplinary meetings or in dis-
cussion with patients), but maximum intensity projection 
images should not be used alone for reading because appar-
ent false-positive and false-negative disease assessments can 
occur (eg, due to T2 shine-through, respiratory motion sig-
nal dephasing, sparse disease pattern) (37,38). Serial volume 
maximum intensity projection image comparisons can be 
facilitated by using windowing techniques; for example, by 
maintaining window width between studies but adjusting the 
window level to a normal tissue such as muscle or subcutane-
ous fat for each time point.
The evaluation of source images obtained with DW MRI se-
quences at b values of 800–900 sec/mm2 is based on comparing 
high b-value image intensity to adjacent muscle signal intensity, 
but assessments of ADC maps are numeric (unit, 31023 mm2/
sec or 31026 mm2/sec [µm2/sec]).
The definitions for hypointense and hyperintense signal on im-
ages at b values of 800–900 sec/mm2 remain subjective but can 
be gauged by using adjacent muscle as the reference background 
tissue (39–41).
Not all hyperintense bone lesions on high b-value images are 
malignant in nature. Causes for apparent high b-value focal bone 
lesions that are false-positive for cancer include bone marrow 
edema caused by fractures, osteoarthritis, infection, bone infarcts, 
vertebral hemangiomas, chondromas, cysts, focal fat-poor bone 
marrow, and artifacts around metal implants (42,43). Further-
more, successfully treated focal lesions may undergo liquid trans-
formation and can stand out on DW images due to the T2 shine-
through phenomenon.
The presence of focal bone lesions can also be obscured when 
background bone marrow hyperplasia occurs as the result of ane-
mia, as a rebound after high-dose therapy, or due to use of bone 
marrow growth factors. This is commonly encountered after 
allogenic stem cell transplantation. The detection of skeletal 
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Figure 2: MR images show patterns of myeloma dis-
ease. A, C, E, G, I, Axial diffusion-weighted MR images 
(b value of 900 sec/mm2). B, D, F, H, J, Corresponding 
apparent diffusion coefficient (ADC) maps. A, B, Images 
show appearances of normal adult bone marrow. C, D, 
Images demonstrate focal lesion (white arrows) greater 
than 5 mm, which returns higher signal intensity at b 
value of 900 sec/mm2 than does muscle and background 
marrow, and which has ADC resembling soft tissue that 
is higher than background marrow but lower than fluid, 
as seen in bowel anteriorly (black arrow). E, F, Images 
show marrow that has diffusely higher signal intensity 
than does muscle and returns ADC that is similar to soft 
tissues. G, H, Images demonstrate focal lesion (arrows) 
that returns higher signal intensity than does muscle and 
background marrow at b value of 900 sec/mm2. How-
ever, background marrow is also higher signal intensity 
than muscle, suggesting background diffuse marrow hy-
percellularity that is confirmed on ADC map. I, J, Images 
show widespread heterogeneity with tiny nodular areas 
of altered diffusion signal (5 mm) with preserved normal 
marrow between them. This variegated or micronodular 
pattern is confirmed on, K, water-only Dixon and, L, sagit-
tal T1 images. M, Image shows paramedullary soft-tissue 
disease that is in direct continuity with marrow disease, 
as demonstrated around left femur in M (black arrow). In 
contrast, N, extramedullary disease is soft-tissue disease 
that is not in continuity with marrow disease, as demon-
strated in M and N (white arrows), which show ischiorec-
tal fossa and pancreatic disease, respectively.
lesions at whole-body DW imaging may also be im-
paired in areas of body movement such as the ribs 
and occasionally in the sternum, but review of the 
maximum intensity projections of high b-value im-
ages can be helpful. Evaluation of skull vault lesions 
is best performed by evaluating the axial source 
high b-value images and corresponding Dixon fat 
fraction images. The visibility of skull base disease is 
generally impaired because of susceptibility effects 
and because of the adjacent high signal intensity of 
the brain on high b-value images.
Strategies for mitigating false-positive results due 
to DW imaging hyperintensities include direct cor-
relations with morphologic appearances, including 
T1-weighted spin-echo and Dixon images (44,45) 
and ADC values (ADC values of normal bone mar-
row are generally below 600–700 µm2/sec and viable 
tumor lies between 700–1400 µm2/sec (46,47,48). 
Tumor ADC values greater than or equal to 1400 
µm2/sec are usually observed in treated or necrotic 
disease. However, myeloma is a disease where there is 
intermixing of myeloma cells, fat, and myeloid cells 
within the marrow space, the relative proportions of which can 
alter ADC values, which must also be considered (30,49). Every 
suspicious lesion on high b-value images should be evaluated with 
other sequences, particularly Dixon fat fraction images by using 
coregistration tools.
The authors also recognize there are limitations of the 
ADC cutoff values referred to previously, which are partly 
related to the fact that ADC values depend on the choice 
of b values of DW images used for calculations (hence, the 
constraints on the recommended choices of b values). The 
ADC values may also depend on the diffusion time achiev-
able with diffusion sequences (which is dependent on se-
quence waveforms and imager specifications). Aside from 
imaging parameters, ADC quantification is influenced by 
additional factors, which are patient related caused by sus-
ceptibility effects (eg, implants, air-tissue interfaces) or mo-
tion and technique related caused by the specifications of 
Messiou et al
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DW imaging. Otherwise, the ADC values can be erroneous, 
reflecting the distribution of noise on the images.
Preferably, water signal should be detectable for the as-
sessed region on all b-value images. However, the absence of 
tissue signal intensity on very high (b value of 800–900 sec/
mm2) b-value images does not in and of itself invalidate a 
tissue from ADC measurements. Where applicable, if signal 
intensity is detectable on low and intermediate b-value im-
ages, then ADC measurements should be performed. ADC is 
generally considered to be a parameter with good reproduc-
ibility, and the coefficient of variation in myeloma-involved 
bone marrow has been reported as low as 2.8% (31).
Diffuse disease.—For patients with a suspected new diagnosis 
of myeloma, diffuse disease can be suspected from diffuse de-
creased signal on T1 fast spin-echo or Dixon in-phase and fat-
only images, and diffuse increased signal throughout the marrow 
relative to normal muscle on high b-value images (Fig 2) (48). 
Suspicion for diffuse infiltration can be documented but must 
be confirmed with trephine biopsy, and imaging must be per-
formed to state whether posterior iliac crest sampling is likely 
to be representative. An ADC measurement using a region of 
interest greater than 1 cm2 of representative involved bone mar-
row can be measured particularly where diffuse infiltration is 
suspected (50).
the MRI unit, including magnetic field strength, gradients, 
and coils (39). Where there are deviations from the recom-
mended b values due to machine, software, or technical 
factors, then institutions can determine their own muscle-
normalized high b-value signal intensity and ADC cutoff 
values for normal marrow and for untreated bone marrow 
lesions as described by Padhani et al (41).
Size measurements.—The International Myeloma Working 
Group stipulates 5 mm as the threshold for defining an un-
equivocal focal active lesion (Fig 2). Therefore, lesions less than 
or equal to 5 mm should be documented for surveillance but 
precise measurements not given due to limitations on image 
resolution. Lesions greater than 5 mm but less than 1.0 cm 
with appropriate signal characteristics should be documented 
as focal active disease, but once again, precise measurements 
not given.
In rare instances when there are unequivocal malignant 
lesions less than 1.0 cm and entry to clinical trials mandates 
the presence of measurable disease, a relaxation of the thresh-
old of greater than or equal to 1.0 cm may be applied in the 
knowledge of the caveats on image resolution.
Obtaining ADC values.—ADC measurements should only 
be obtained from lesions or areas when water is detectable at 
Table 1: Sequence Components for Whole-Body MRI Examinations
No. Sequence Description Core Clinical Protocol
Comprehensive Assessments  
for Research
1 Whole spine: sagittal, T1-weighted, fast spin-echo,  
 section thickness of 4–5 mm
Yes Yes
2 Whole spine: sagittal, T2, STIR or fat-suppressed  
 T2-weighted, section thickness of 4–5 mm
Yes Yes
3 Whole body (vertex to knees): T1-weighted,  
  gradient-echo Dixon technique. Fat and water image  
reconstructions are mandatory and should be used to  
generate fat fraction maps (FF = F/(F+W) 3 100%). 
(A 3D fast spin-echo T1-weighted sequence offering  
multiplanar capability may be performed as an alternative  
to replace sequences 1 and 3.)
Axial or coronal (5 mm)* Axial and coronal
4 Whole body (vertex to knees): axial, diffusion-  
  weighted, STIR fat suppression, 5 mm contiguous  
sectioning, multiple stations.
2 b values (50–100 sec/mm2  
 and 800–900 sec/mm2)
3 b values  
 (additional 500–600 sec/mm2)
 ADC calculations with monoexponential data fitting
 3D MIP reconstructions of highest b-value images†
5 Whole body (vertex to knees): axial, T2-weighted,  
  fast spin-echo without fat suppression, 5-mm contiguous  
sectioning, multiple stations, preferably matching the 
diffusion-weighted images
Optional Yes
6 Regional assessments: for example, symptomatic or known sites  
  outside standard field of view, through sites of suspected  
cord compression, nerve root involvement, extramedullary disease
Usually not Optional
Note.—ADC = apparent diffusion coefficient, MIP = maximum intensity projection, STIR = short inversion time inversion-recovery, 3D = 
three-dimensional.
* 5-mm axial imaging may be chosen to match section thickness of diffusion-weighted imaging to facilitate image review.
† Whole-body 3D MIP images displayed as a sequence of coronal or sagittal MIP images rotating in the axial plane (3 degrees of rotation 
per frame) by using an inverted gray scale.
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5, highly likely to be progressing (Table 3). More detailed case 
report forms for research are included in Appendix E1 (online).
Clinical Trial Assessments
Most clinical reports will be performed as outlined in the previous 
section. However, academic centers wishing to collect assess-
ments of disease for clinical trials may require more sophis-
ticated scoring systems. Detailed instructions for a proposed 
clinical trials scoring system and an exemplar case study can 
be found in Table E2 and Figure E1 (Appendix E1 [online]).
Knowing that quantitative assessments such as ADC and fat 
fraction measurements can change over time (for example, re-
sponding myeloma may show an early increase in ADC values at 
4–6 weeks due to cell death, followed by a decrease in ADC with 
return of normal fatty marrow [51]), it is difficult to be prescriptive 
regarding the frequency of imaging follow-up. Therefore, for cor-
relation, we recommend that imaging should coincide with clini-
cal routines where serum and marrow assessments are performed.
Conclusion
The Myeloma Response Assessment and Diagnosis System 
(MY-RADS) system provides comprehensive characteriza-
tion of the myeloma state, both at diagnosis and the start of 
treatment, as well as over time as the disease evolves during 
Although useful data are emerging to differentiate normal 
age-matched bone marrow from diffuse disease by using ADC 
(47,48,49), whole-marrow quantitative measures of ADC are not 
yet practical measures and therefore not part of the MY-RADS 
standard. However, marrow ADC values above 600–700 µm2/
sec in a nontreated and newly diagnosed patient with multiple 
myeloma could be used to increase confidence for the diagnosis 
of diffuse marrow involvement (8). For patients who have been 
treated, there is increased potential for false-positive appearances 
of diffuse infiltration due to rebound hypercellularity related to 
treatment effects or granulocyte colony–stimulating factor (8). 
Therefore, when diffuse disease is suspected, administration of 
granulocyte colony–stimulating factor must be excluded and if 
progression is suspected based on suspicion for diffuse infiltra-
tion alone, then this must be confirmed with serum biochemis-
try and/or marrow sampling.
Structured Reporting
Structured clinical reporting (Table 2) should be performed for 
each examination. For response assessments, we recommend 
that response assessment category, or RAC, be assigned accord-
ing to anatomic regions. For each region, RAC can be assigned 
by using the criteria given in Table 3. The RAC should use a 
five-point scale as follows: 1, highly likely to be responding; 2, 
likely to be responding; 3, stable; 4, likely to be progressing; 
Table 2: Clinical Reporting Template
Clinical Reporting Template Notes
Indication
Technique Core or comprehensive protocol, additional sequences and deviations
Findings
 Dates of previous examinations
 Evaluation of bones Spine and then head to thighs in descending order
 Measurements of up to five focal lesions and  
  document pattern of marrow infiltration
Normal, focal, focal on diffuse, diffuse, micronodular*
 Paramedullary or extramedullary sites Measure size
 Vertebral fractures Document presence and use a combination of morphologic and  
  functional imaging to characterize as benign versus malignant.  
Source.—Reference 52.
 RAC for each anatomic region† Cervical spine, thoracic spine, lumbar spine, pelvis, long bones, skill, ribs or 
other
  1: Highly likely to be responding
  2: Likely to be responding
  3: Stable
  4: Likely to be progressing
  5: Highly likely to be progressing
 Posterior iliac crests Is trephine likely to be representative?
 Incidental findings Incidental lesions including avascular necrosis, which may be a complication  
 of myeloma treatment. Source.—Reference 53.
Conclusion
 Summary statement, RAC score, heterogeneity,  
   recommendations including for investigation  
of equivocal findings
State level of concern regarding incidental findings
Note.—RAC = response assessment category.
* See also Figure 2.
† See also Table 3.
Messiou et al
Radiology: Volume 291: Number 1—April 2019  n  radiology.rsna.org 11
Table 3: MY-RADS Response Assessment Categories
RAC Descriptions*
1: Highly likely to be responding
 Return of normal fat containing marrow in areas previously  
  infiltrated by focal or diffuse myelomatous infiltration
 Unequivocal decrease in number or size of focal lesions
 Conversion of a packed bone marrow infiltrate into  
   discrete nodules, with unequivocal decrease in tumor  
load in the respective bone marrow space
 Decreasing soft tissue associated with bone disease
 Emergence of intra- or peritumoral fat within/around  
  focal lesions (fat dot or halo signs)
 Previously evident lesion shows increase in ADC from  
  1400 µm2/sec to .1400 µm2/sec
 40% increase in ADC from baseline with corresponding  
   decrease in normalized high b-value signal intensity; 
morphologic findings consistent with stable or responding 
disease
 For soft-tissue disease, RECIST version 1.1 criteria for PR/CR
2: Likely to be responding
 Evidence of improvement but not enough to fulfill  
  criteria for RAC 1. For example:
  Slight decrease in number/size of focal lesions
  Previously evident lesions showing increases in ADC  
   from 1000 µm2/sec to ,1400 µm2/sec
  .25% but ,40% increase in ADC from baseline with  
    corresponding decrease in high b-value signal intensity; 
morphologic findings consistent with stable or respond-
ing disease
 For soft-tissue disease, RECIST version 1.1 not meeting  
  requirements for PR
3: No change
 No observable change
4: Likely to be progressing
 Evidence of worsening disease, but not enough to  
  fulfill criteria for RAC 5
 Equivocal appearance of new lesion(s)
 No change in size but increasing signal intensity on high  
    b-value images (with ADC values ,1400 µm2/sec) con-
sistent with possible disease progression
 Relapsed disease: reemergence of lesion(s) that  
  previously disappeared or enlargement of lesion(s)  
  that had partially regressed/stabilized with prior treatments
 Soft tissue in spinal canal causing narrowing not associated  
  with neurologic findings and not requiring radiation therapy
 For soft-tissue disease, RECIST version 1.1 criteria  
  not meeting requirements for PD
5: Highly likely to be progressing
 New critical fracture(s)/cord compression requiring radiation  
   therapy/surgical intervention; only if confirmed as malig-
nant with MRI signal characteristics
 Unequivocal new focal (.5 to 10 mm)/diffuse area(s)  
  of infiltration in regions of previously normal marrow
 Unequivocal increase in number/size of focal lesions
 Evolution of focal lesions to diffuse neoplastic pattern
 Appearance/increasing soft tissue associated with bone disease
 New lesions/regions of high signal intensity on high  
  b-value images with ADC value between 600–1000 µm2/sec
RAC Descriptions*
 For soft-tissue disease, RECIST version 1.1 criteria meeting  
  requirements for PD
Note.— Multiple criteria determine response assessment cat-
egory (RAC). For RAC 1 or 2, when diffusion-weighted imaging 
and morphology are discordant, consideration should be given 
to pitfalls such as T1 pseudoprogression and bone marrow fat 
reemergence (the latter two may not increase apparent diffusion 
coefficient [ADC] values). MY-RADS = Myeloma Response As-
sessment and Diagnosis System, RECIST = Response Evaluation 
Criteria in Solid Tumors.
* RECIST version 1.1 categories for soft-tissue disease are as fol-
lows. Complete response (CR): Disappearance of all target lesions. 
Partial response (PR): At least a 30% decrease in the sum of the 
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therapy and follow-up. MY-RADS recommendations are likely 
to fulfill the need to promote standardization and diminish 
variations in the acquisition, interpretation, and reporting of 
whole-body MRI and allow better response assessments. This 
system is designed for guiding patient care but has potential 
for incorporation into clinical trials when lesion measurements 
become more important. MY-RADS allows the categoriza-
tion of patients with specific patterns of disease for clinical 
trial stratification. MY-RADS requires validation within clini-
cal trials, including assessments of reproducibility. We suggest 
that MY-RADS be evaluated in studies that assess the effects 
of life-prolonging myeloma treatments, including novel treat-
ment strategies such as immunotherapy. In these studies, MY-
RADS assessments of the depth and heterogeneity of response 
should be compared with established myeloma response cri-
teria. Given the high rates of complete response seen in pa-
tients with multiple myeloma with new treatment approaches, 
new response categories need to be defined that can identify 
responses that are deeper than those conventionally defined as 
complete response.
Correlations with quality-of-life measures, rates of skeletal 
events, and rates of progression-free survival are also needed. The 
latter are prerequisites for the introduction of whole-body MRI 
into longer term follow-up registry studies that prospectively 
collect appropriate meta-data, which would allow objective as-
sessments of whether whole-body MRI is effective in supporting 
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patient care and drug development. It is anticipated that, as evi-
dence accrues from clinical trials, more specific recommendations 
and/or algorithms incorporating MY-RADS will emerge. Thus, 
we recommend that Myeloma Response Assessment and Diagno-
sis System is now evaluated in clinical trials to assess its impact on 
the clinical practice of myeloma.
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